Seeking Alpha
Profile| Send Message|
( followers)
Earnings season is well underway with Gilead (NASDAQ:GILD), Genzyme (GENZ), Biogen Idec, and Roche (OTCQX:RHHBY) all having reported their second quarter results. The numbers have been a mixed bag and there are some big questions overhanging key players in the industry. Some investors are looking beyond the quarter, but what they see isn’t always encouraging.
We spoke to Adam Feuerstein, senior columnist for The, about how the second quarter numbers are shaping up, what red flags may be out there, and how investors are looking at the results these days.
Source: Investors Consider Biotech's Latest Results

Check out Seeking Alpha’s new Earnings Center »